fr   en
Acquisitions
Select a company :
Choose date:
«      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »      
Date Acquiring pharma company Acquired biotech company Amount Terms / other
2007-03-12 Oxford Biomedica (UK) Oxxon (UK) £16 million (Euro23.4 million) See details
2007-03-12 Bolton (Poland) BioPartners Holdings (Switzerland) $78 million (Euro59 million) See details
2007-03-12 Takeda Pharmaceutical (Japan) Paradigm Therapeutics (UK) not disclosed See details
2007-03-01 EUSA Pharma (UK/USA) OPi (France) Not disclosed See details
2007-02-20 Shire (UK) New River Pharmaceuticals (USA) $2.6 billion See details
2007-02-01 AstraZeneca (UK) Arrow Therapeutics (UK) $150 million in cash See details
2007-01-09 GSK (GB) Praecis Pharmaceuticals (USA) $54.8 million See details
2006-12-22 Galapagos (Belgium) Proskelia, a division of Prostrakan (UK) The operation can be broken down into three parts, an initial payment of Euro12.5 million, plus Euro5 million Euro for the license to E2G and up to 14.5 million Euro depending on revenues that Galapagos may generate through preclinical programmes acquired from Proskelia. See details
2006-12-08 Protherics (UK) Macromed (USA) $25 million See details
2006-12-08 GSK (UK) Domantis (UK) £230 million (Euro340.5 million) See details
2006-12-06 Intercell (Austria) Pelias (Germany) not disclosed See details
2006-12-06 Galapagos NV (Belgium) Inpharmatica (UK) Euro12.5 million See details
2006-11-30 Perkin Elmer (USA) Evotec Technologies (Germany) Euro23 million See details
2006-11-27 Crucell (The Netherlands) SBL Vaccine (Sweden) Euro39.4 million See details
2006-11-20 Actelion (Switzerland) CoTherix (USA) $420 million See details
«      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10      »